Apatinib and Irinotecan Combination Treatment in Esophageal Squamous Cell Carcinoma

NCT02645864 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

DRUG: Apatinib
DRUG: Irinotecan

Sponsor

Peking University

Collaborators

[object Object]